Related Experiment Video
Updated: Feb 28, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Taming the Achilles' Heel: A Chemical and Structural Design to Address Off-Target Effects in siRNA Therapeutics
Rohith Pavan Parvathaneni1, Nithiyanandan Krishnan2, Nikolai Hempel3
1Translational Chemical Biology, Science for Life Laboratory, Department of Chemistry, Ångström Laboratory, Uppsala University, 751 21 Uppsala, Sweden.
None:
Off-target effects represent one of the major bottlenecks for RNA interference (RNAi) technology. To address this issue, we present a novel strategy by combining seed-region chemical modification with an extended 3'-overhang on the sense strand (SS) to mitigate SS-mediated and miRNA-like nontargeted interactions. To modify the seed-region, we developed a novel 2'-diol modification that was selectively installed at different positions within the seed-region of siRNA. For this purpose, we synthesized universal 2'-diacetate phosphoramidites that yielded a free 2'-diol functionality after standard deprotection of oligonucleotides. The 2'-diol moieties with single (positions 3-7) and dual (6 + 7) insertions in the seed-region decreased the melting temperature (T m) by ca. -1 to -4.0 °C, imposing thermodynamic asymmetry. To improve the end-asymmetry of siRNA, we developed a structurally unsymmetrical siRNA (US-siRNA) design (five-nucleotides at the 3'-overhang region of SS), which together with seed-region modifications significantly increased the relative RISC loading of antisense strand (AS) with respect to their canonical sense variants. Overall, our rational design of chemical modifications of the seed-region with a 2'-diol moiety, in concert with the US-siRNA design, furnishes a simple, modular strategy to minimize off-target effects while maintaining the on-target RNAi activity.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers

